Fulcrum Therapeutics to Participate in Upcoming December Conferences

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.^® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following conferences:

• Piper Sandler 36^th Annual Healthcare Conference
  December 3, 2024
  Fireside Chat at 12:00 pm ET, Participation link: HERE
  New York, New York

• Citi 2024 Global Healthcare Conference
  December 4, 2024
  Miami, Florida

• Evercore ISI 7th Annual HealthCONx Conference
  December 5, 2024
  Miami, Florida

The webcast of the Piper Sandler fireside chat will be accessible by visiting the "Events and Presentations" section of Fulcrum Therapeutics’ website at https://ir.fulcrumtx.com/events-and-presentations. A replay of the webcasts will be available on Fulcrum Therapeutics’ website for at least 30 days following the presentations.

About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead program in clinical development is pociredir, a small molecule designed to increase expression of fetal hemoglobin and in development for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit www.fulcrumtx.com and follow us on Twitter/X (@FulcrumTx) and LinkedIn.

Contact:
Chris Calabrese
LifeSci Advisors, LLC
[email protected]
917-680-5608

You May Also Be Interested In

• She Made it – the Youngest South African Woman to Swim the Channel
• Denver HVAC Startup Reaches 2,132 Jobs and 69 Employees in Year One
• Best Crypto Presale: AlphaPepe at $0.02789 Keeps the $1 Roadmap Trade Alive With Public Trading Still Ahead